2015 A highly immunogenic and protective MERS-Coronavirus vaccine based on recombinant MV vaccine platform

52 Pages·2015·9.31 MB·English

1

A highly immunogenic and protective MERS-Coronavirus vaccine based on recombinant
1

MV vaccine platform
2

Anna H. Malczyka,b , Alexandra Kupkec,d,*, Steffen Prüfera,*, Vivian A. Scheupleina, Stefan
3

Hutzlera, Dorothea Kreuze, Tim Beissertf, Stefanie Bauere, Stefanie Hubich-Raug, Christiane
4

Tonderaa, Hosam Shams Eldinc,d, Jörg Schmidtc,d, Júlia Vergara-Alertc,d, Yasemin Süzera, Janna
5

Seifrieda, Kay-Martin Hanschmannh, Ulrich Kalinkei,k, Susanne Heroldl, Ugur Sahinf,g, Klaus
6

Cichuteka,b, Zoe Waiblerb,e, Markus Eickmannc,d, Stephan Beckerc,d, and Michael D.
7

Mühlebacha,b,#
8

9

Oncolytic Measles Viruses and Vaccine Vectors,a Novel Vaccination Strategies and Early
10

Immune Responses,e Biostatistics,h Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, Langen,
11

Germany; German Center for Infection Research, Langen, Germanyb; Institut für Virologie,
12

Philipps Universität Marburg, Marburg, Germanyc; Universities Gießen & Marburg Lung Center
13

(UGMLC), Department of Internal Medicine II, Section of Infectious Diseases, Gießen,
14

Germanyl; German Center for Infection Research, Marburg, Germanyd; TRON gGmbH, Mainz,
15

Germanyf; Universitätsmedizin Mainz, Mainz, Germanyg; Institute for Experimental Infection
16

Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture
17

between the Hannover Medical School and the Helmholtz Centre for Infection Research,
18

Hannover, Germanyi; German Center for Infection Research, Hannover, Germanyk

19

#Address correspondence to Dr. Michael Mühlebach,